Elmwood Wealth Management Inc. Sells 150,000 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

Elmwood Wealth Management Inc. lowered its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 6.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,025,740 shares of the company’s stock after selling 150,000 shares during the quarter. Caribou Biosciences makes up approximately 1.3% of Elmwood Wealth Management Inc.’s holdings, making the stock its 26th biggest holding. Elmwood Wealth Management Inc.’s holdings in Caribou Biosciences were worth $3,221,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in CRBU. PFM Health Sciences LP grew its stake in shares of Caribou Biosciences by 5.5% during the 3rd quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock worth $8,441,000 after acquiring an additional 223,299 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Caribou Biosciences by 25.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after acquiring an additional 536,162 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Caribou Biosciences by 6.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after acquiring an additional 124,782 shares in the last quarter. FMR LLC grew its stake in shares of Caribou Biosciences by 7.4% during the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after acquiring an additional 109,606 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Caribou Biosciences during the 2nd quarter worth approximately $2,432,000. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Stock Performance

Shares of NASDAQ:CRBU traded down $0.12 during midday trading on Monday, hitting $1.53. 2,362,074 shares of the stock were exchanged, compared to its average volume of 1,683,964. The stock has a market capitalization of $138.09 million, a price-to-earnings ratio of -0.92 and a beta of 2.34. The business’s 50-day moving average price is $2.01 and its 200 day moving average price is $2.00. Caribou Biosciences, Inc. has a 12 month low of $1.50 and a 12 month high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The business had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million. As a group, sell-side analysts expect that Caribou Biosciences, Inc. will post -1.64 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Bank of America decreased their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Caribou Biosciences in a report on Friday, November 15th. Finally, Citigroup dropped their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Caribou Biosciences presently has an average rating of “Buy” and a consensus price target of $10.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.